By Katherine Hamilton
Progyny shares rose Monday after the company said it expects its fourth-quarter financial results to beat previously shared guidance.
The stock advanced 7% to $20.14, its highest price since September.
The New York-based fertility company said it expects revenue, net income and adjusted EBITDA for the quarter ended Dec. 31 to be higher than the ranges it provided in November.
It previously said it anticipated its fourth-quarter revenue to be $266.2 million to $281.2 million, the higher end of which would be a 4% increase from the previous year. It guided for net income between $6.1 million and $9.5 million, and adjusted EBITDA of $37.8 million to $ 42.8 million.
Progyny said it is now expecting higher results because it is seeing improved pacing in activity and treatment volume. The company previously believed member activity would be flat with or decline from the prior year.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
January 13, 2025 12:34 ET (17:34 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。